Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
JCR Expects Strong Returns from Recently In-Licensed DMD Drug: CEO
JCR Pharmaceuticals expects its recently in-licensed Duchenne muscular dystrophy (DMD) treatment givinostat to generate significant long-term profits, CEO Shin Ashida said at a briefing on January 23. The company expects the oral therapy to differentiate itself from existing DMD treatments…
To read the full story
Related Article
- JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
BUSINESS
- Leqembi Iqlik Now under FDA Review for Initiation Phase
January 26, 2026
- Regeneron Japan Launches Scholarship for STEM-Oriented High School Students
January 26, 2026
- JCR Expects Strong Returns from Recently In-Licensed DMD Drug: CEO
January 26, 2026
- Solasia to Grant MAAB Rights to Antiemetic Drug in China
January 26, 2026
- Toho Seeks Additional Disclosure from 3D over Proposed Share Purchases
January 26, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…